Search Results

Showing results 1271 - 1280 for leonard

Faculty Listing | Page 16 | Weill Department of Medicine

... Clinical Profile Research Profile Leonard Horovitz, M.D. Clinical Instructor in Medicine Research Profile...

https://medicine.weill.cornell.edu/about-us/faculty-listings?page=15

Faculty Listing | Page 29 | Weill Department of Medicine

... Assistant Professor John P Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology...

https://medicine.weill.cornell.edu/about-us/faculty-listings?page=28

2013-2-weill-cornell-medicine-brain-storm.pdf

... to remove, his col- leagues say. Spinal surgeons such as Roger Härtl, MD, the Leonard and Fleur Harlan...

https://neurosurgery.weillcornell.org/sites/default/files/2013-2-weill-cornell-medicine-brain-storm.pdf

KL2 Alumnus, Bishoy Faltas, Awarded R37 MERIT Award Extension and Department of Defense Grant | Clinical & Translational Science Center

...-Presbyterian Hospital. Dr. Faltas also serves as the Gellert Family-John P. Leonard, MD, Research Scholar...

https://ctscweb.weill.cornell.edu/education-training/e-news-digest/kl2-alumnus-bishoy-faltas-awarded-r37-merit-award-extension-and

Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma. | Pathology & Laboratory Medicine

..., S Rajkumar V, Coleman M, Kumar S, Mark T, Dispenzieri A, Pearse R, Gertz MA, Leonard J, Lacy MQ...

https://pathology.weill.cornell.edu/research/publications/clarithromycin-biaxin-lenalidomide-low-dose-dexamethasone-bird-versus

Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy. | Pathology & Laboratory Medicine

..., Pearse RN, Ely S, Leonard JP, Mazumdar M, Chen-Kiang S, Coleman M Journal Br J Haematol Volume 138...

https://pathology.weill.cornell.edu/research/publications/lenalidomide-induced-myelosuppression-associated-renal-dysfunction-adverse

Outcome of deferred initial therapy in mantle-cell lymphoma. | Pathology & Laboratory Medicine

..., Niesvizky R, Ely S, Diliberto M, Melnick A, Knowles DM, Chen-Kiang S, Coleman M, Leonard JP Journal...

https://pathology.weill.cornell.edu/research/publications/outcome-deferred-initial-therapy-mantle-cell-lymphoma

Induction of prolonged early G1 arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3Kδ inhibition through PIK3IP1. | Pathology & Laboratory Medicine

... P, Di Liberto M, Huang X, Ely S, Lannutti BJ, Leonard JP, Mason CE, Chen-Kiang S Journal Cell Cycle...

https://pathology.weill.cornell.edu/research/publications/induction-prolonged-early-g1-arrest-cdk4cdk6-inhibition-reprograms-lymphoma

Postibrutinib outcomes in patients with mantle cell lymphoma. | Pathology & Laboratory Medicine

... Article Year of Publication 2016 Authors Martin P, Maddocks K, Leonard JP, Ruan J, Goy A, Wagner...

https://pathology.weill.cornell.edu/research/publications/postibrutinib-outcomes-patients-mantle-cell-lymphoma

A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma. | Pathology & Laboratory Medicine

..., Inghirami G, Diliberto M, Chen-Kiang S, Leonard JP Journal Blood Volume 133 Issue 11 Pagination 1201-1204...

https://pathology.weill.cornell.edu/research/publications/phase-1-trial-ibrutinib-plus-palbociclib-previously-treated-mantle-cell

Showing results 1271 - 1280 for leonard